Pneumonia Therapeutics Market: By Therapeutics (Prevention Vaccines and Treatment Drugs), Distribution Channel (Hospitals, Pharmaceutical Stores, and Others), Age Group (Pediatric, Adult, and Geriatric), And Region (North America, Europe, Asia Pacific, Latin America, And MEA) And Forecast To 2029  

Purchase Option

$ 4400
$ 6600
$ 8900

Pneumonia Therapeutics Market size was valued at USD 14,956.4 million in 2022 and is expected to grow at a CAGR of 8.7% from 2023-2029. Pneumonia is an inflammatory medical disorder that disturbs the alveoli and air sacs in the lungs. Pathogens such as viruses, bacteria, and fungi are the leading cause of pneumococcal infection using inhalation of air-borne droplets from coughing or sneezing. Pneumonia can also happen through contact with surfaces and objects that are soiled with pneumonia-causing viruses and bacteria.  According to the kind of case, the medicines are to be given. For example, if pneumonia is produced by bacteria, an antibiotic is prescribed. Pneumonia therapeutics comprise the approaches such as drugs and vaccinations that can support managing of the infection. The infection can be severe but are predominantly lethal to children, infants, and individuals over 65. The rising prevalence of pneumococcal disease can lead to the growth of the pneumonia therapeutics market. Moreover, the growing pollution level in the environment, the introduction of preventive vaccination programs, and improved standards introduced by healthcare facilities over the market are some primary factors that can boost the global pneumonia therapeutics market share. Apart from these, the increased prevalence rate of lung illnesses worldwide can also accelerate the market in the future. However, some factors, such as the absence of patient awareness and restricted access to therapy, may restrain the growth of the market. The current clinical trials for the expansion of vaccine and drug molecules can create an opportunity for the growth of the global pneumonia therapeutics market.

Pneumonia Therapeutics Market Key Developments:

  • In October 2022, BioLink received funds to develop a Covid-19 pneumonia treatment.
  • In August 2022, Pfizer announced positive top-line results from the Phase 3 Study of the 20-valent pneumococcal conjugate vaccine in infants.

Pneumonia Therapeutics Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

8.7%

Largest Market

Asia Pacific

Fastest Growing Market

North America
Pneumonia Therapeutics Market Dynamics

One of the major reasons for the growth of the global pneumonia therapeutics market is the growing funding for the development of the new product to report disease management. The high brutality of pneumonia, together with high demand from the market, is expected to propel the growth of the market in the forecast period. For example, in the current scenario, various companies working in the pneumonia therapeutics market, which comprises market giants like Merck, Pfizer, and GSK, are maneuvering huge capital and putting massive efforts into such research and development activities. This is further enhanced by positive clinical trials and regulatory approvals from concerned authorities.

Pneumonia Therapeutics Market Segmentation

By Therapeutics
  • Prevention Vaccines
  • Treatment Drugs
By Distribution Channel
  • Hospitals
  • Pharmaceutical Stores
  • Others
By Age Group
  • Pediatric
  • Adult
  • Geriatric

Frequently Asked Questions

The absence of patient awareness and restricted access to therapy can hinder the market growth.

The current clinical trials for the expansion of vaccine and drug molecules can create an opportunity for the growth of the global pneumonia therapeutics market.

In September 2022, FDA approved Nabriva Therapeutics’ Xenleta (lefamulin) to treat community-acquired bacterial pneumonia (CABP) as the first in a new class of antibiotics called pleuromutilins, which target a different protein synthesis binding site than older competitors.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
1. Executive Summary
2. Global Pneumonia Therapeutics Market Introduction
2.1. Global Pneumonia Therapeutics Market – Taxonomy
2.2. Global Pneumonia Therapeutics Market – Definitions
2.2.1. Therapeutics
2.2.2. Distribution Channel
2.2.3. Age Group
2.2.4. By Region
3. Global Pneumonia Therapeutics Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Pneumonia Therapeutics Market Dynamic Factors - Impact Analysis
3.6. Global Pneumonia Therapeutics Market – Competition Landscape
4. Global Pneumonia Therapeutics Market, By Therapeutics, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
4.1. Prevention Vaccines
4.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
4.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
4.1.3. Market Opportunity Analysis
4.2. Treatment Drugs
4.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
4.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
4.2.3. Market Opportunity Analysis
5. Global Pneumonia Therapeutics Market, By Distribution Channel, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
5.1. Hospitals
5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Pharmaceutical Stores
5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Others
5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
6. Global Pneumonia Therapeutics Market, By Age Group, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
6.1. Pediatric
6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Adult
6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Geriatric
6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
7. Global Pneumonia Therapeutics Market Forecast, By Region, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
7.1. North America
7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Europe
7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Asia-Pacific
7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Latin America
7.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
7.5. Middle East and Africa
7.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.5.3. Market Opportunity Analysis
7.6. Global Pneumonia Therapeutics Market - Opportunity Analysis Index, By Therapeutics, By Distribution Channel, By Age Group, and Region, 2023 - 2029
8. North America Pneumonia Therapeutics Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
8.1. Therapeutics Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
8.1.1. Prevention Vaccines
8.1.2. Treatment Drugs
8.2. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
8.2.1. Hospitals
8.2.2. Pharmaceutical Stores
8.2.3. Others
8.3. Age Group Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
8.3.1. Pediatric
8.3.2. Adult
8.3.3. Geriatric
8.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
8.4.1. USA
8.4.2. Canada
8.5. North America Pneumonia Therapeutics Market - Opportunity Analysis Index, By Therapeutics, By Distribution Channel, By Age Group, and Country, 2023 - 2029
8.6. North America Pneumonia Therapeutics Market Dynamics – Trends
9. Europe Pneumonia Therapeutics Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
9.1. Therapeutics Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1. Prevention Vaccines
9.1.2. Treatment Drugs
9.2. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.2.1. Hospitals
9.2.2. Pharmaceutical Stores
9.2.3. Others
9.3. Age Group Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.3.1. Pediatric
9.3.2. Adult
9.3.3. Geriatric
9.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.4.1. Germany
9.4.2. UK
9.4.3. France
9.4.4. Spain
9.4.5. Italy
9.4.6. Rest of Europe
9.5. Europe Pneumonia Therapeutics Market - Opportunity Analysis Index, By Therapeutics, By Distribution Channel, By Age Group, and Country, 2023 - 2029
9.6. Europe Pneumonia Therapeutics Market Dynamics – Trends
10. Asia-Pacific Pneumonia Therapeutics Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
10.1. Therapeutics Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Prevention Vaccines
10.1.2. Treatment Drugs
10.2. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.2.1. Hospitals
10.2.2. Pharmaceutical Stores
10.2.3. Others
10.3. Age Group Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.3.1. Pediatric
10.3.2. Adult
10.3.3. Geriatric
10.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.4.1. China
10.4.2. India
10.4.3. Japan
10.4.4. ASEAN
10.4.5. Australia & New Zealand
10.4.6. Rest of Asia-Pacific
10.5. Asia-Pacific Pneumonia Therapeutics Market - Opportunity Analysis Index, By Therapeutics, By Distribution Channel, By Age Group, and Country, 2023 - 2029
10.6. Asia-Pacific Pneumonia Therapeutics Market Dynamics – Trends
11. Latin America Pneumonia Therapeutics Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
11.1. Therapeutics Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Prevention Vaccines
11.1.2. Treatment Drugs
11.2. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.2.1. Hospitals
11.2.2. Pharmaceutical Stores
11.2.3. Others
11.3. Age Group Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.3.1. Pediatric
11.3.2. Adult
11.3.3. Geriatric
11.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.4.1. Brazil
11.4.2. Mexico
11.4.3. Rest of Latin America
11.5. Latin America Pneumonia Therapeutics Market - Opportunity Analysis Index, By Therapeutics, By Distribution Channel, By Age Group, and Country, 2023 - 2029
11.6. Latin America Pneumonia Therapeutics Market Dynamics – Trends
12. Middle East and Africa Pneumonia Therapeutics Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
12.1. Therapeutics Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Prevention Vaccines
12.1.2. Treatment Drugs
12.2. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.2.1. Hospitals
12.2.2. Pharmaceutical Stores
12.2.3. Others
12.3. Age Group Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.3.1. Pediatric
12.3.2. Adult
12.3.3. Geriatric
12.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.4.1. Gulf Cooperation Council (GCC) Countries
12.4.2. South Africa
12.4.3. Rest of MEA
12.5. MEA Pneumonia Therapeutics Market- Opportunity Analysis Index, By Therapeutics, By Distribution Channel, By Age Group, and Country, 2023 - 2029
12.6. MEA Pneumonia Therapeutics Market Dynamics – Trends
13. Competition Landscape
13.1. Strategic Dashboard of Top Market Players
13.2. Company Profiles (Introduction, Financial Analysis, Key Therapeuticss, Key Developments, Strategies, and SWOT Analysis)
13.2.1. Abbott Laboratories
13.2.2. Allergan
13.2.3. AstraZeneca
13.2.4. Bayer
13.2.5. Cipla
13.2.6. GlaxoSmithKline Plc.
13.2.7. Lupin Pharmaceuticals Ltd.
13.2.8. Merck
13.2.9. Mylan
13.2.10. Novartis AG
13.2.11. Pfizer, Inc.
14. Research Methodology
15. Key Assumptions and Acronyms
  • Abbott Laboratories
  • Allergan
  • AstraZeneca
  • Bayer
  • Cipla
  • GlaxoSmithKline Plc.
  • Lupin Pharmaceuticals Ltd.
  • Merck
  • Mylan
  • Novartis AG
  • Pfizer, Inc.

Adjacent Markets